期刊文献+

输卵管结扎时间对卵巢癌发生的临床影响 被引量:1

Clinical efficacy of different fixed number of year of tubal ligation in ovarian tumors
原文传递
导出
摘要 目的探讨输卵管结扎时间对卵巢癌的影响。方法选取2010年4月至2014年4月间收治的90例卵巢癌患者作为试验组,并选取同期收治的135例子宫良性肿瘤、盆底疾病行子宫切除患者作为对照组。比较两组患者输卵管结扎及其结扎不同时间段内患者所占比例。结果试验组患者输卵管结扎率显著低于对照组,未结扎率显著高于对照组,组间差异均有统计学意义P〈0.05)。试验组患者结扎时间〈5年、510年、〉10年所占比例与对照组比较,差异无统计学意义(P〉0.05)。浆液性癌患者结扎年时间〈5年、510年、〉10年所占比例与黏液性癌比较,差异无统计学意义(P〉0.05)。结论输卵管结扎可减少卵巢癌的发生率,但卵管结扎时间对卵巢癌发生无明显影响,因而输卵管结扎可以作为一种对卵巢癌的预防措施加以推广。 Objective Explore the tubal ligation time impact on ovarian cancer. Methods Choose between April 2010 and April 2010 Of Linqu County People' s Hospital between 90 cases of ovarian cancer patients as experimental group, and treated 135 cases of benign tumors of uterus at the same time, muck GongQieChu pelvic disease patients as control group. Compare two groups of patients with tubal liga- tion and vasectomy proportion of patients with different time period. Results Significantly lower than the control group, experimental group patients with tubal ligation rate un-neutered rate is significantly higher than the control group, the differences between groups were statistically significant ( P 〈 0. 05 ). Ligation group patients time 〈 5, 5 - 10 years, 〉 10 years proportion compared with control group, there was no sta- tistically significant difference (P 〉 0. 05 ). Serous carcinoma ligation time 〈 5, 5 - 10 years, 〉 10 years the proportion compared with mucinous carcinoma, there was no statistically significant difference (P 〉 0. 05). Conclusion Tubal ligation can decrease the incidence of ovarian cancer, but the egg tube ligation time had no obvious effect on ovarian cancer occurrence, thus tubal ligation can serve as a kind of preventive measures of ovarian cancer may be popularized.
出处 《中国肿瘤临床与康复》 2016年第2期182-184,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 卵巢肿瘤 输卵管结扎 临床影响 Ovarian neoplasms Tubal ligation Clinical efficacy
  • 相关文献

参考文献7

二级参考文献91

  • 1王海花.四种不同方式治疗输卵管异位妊娠临床疗效分析[J].中国药物与临床,2013,13(S1):59-61. 被引量:4
  • 2华克勤,金福明,徐焕,朱芝玲,林金芳,丰有吉.腹腔镜手术治疗早期低危型卵巢恶性肿瘤的价值[J].中华医学杂志,2005,85(3):169-172. 被引量:18
  • 3Moss EL, Hollingworth J, Reynolds TM, The role of CA125 in clinical practice[J]. J C/in Pathol,2005,58(3) :308-312.
  • 4Drapkin R, yon Horsten HH, Lin Y,et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[ J]. Cancer Res, 2005,65(6) :2162-2169.
  • 5Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Res,2003,63 ( 13 ) :3695-3700.
  • 6Montagnana M, Lippi G, Ruzzenente O,et al. The utility of serum human epididymis protein 4 (HFA) in patients with a pelvic mass[J]. J Clin Lab Anal, 2009,23(5) :331-335.
  • 7Li J, Dowdy S, Tipton T, et al. HFA as a biomarker for ovarian and endometrial cancer management[ J]. Expert Rev Mol Diagn, 2009,9(6) :555-566.
  • 8Huhtinen K, Suvitie P, Hiissa J. Serum HFA concentration differentiates malignant ovarian turnouts from ovarian endometriotic cysts[ J]. Br J Cancer, 2009,101 (3) :548.
  • 9Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [ J ]. Gyneeol Oneol, 2008,108 (2) : 402-408.
  • 10Shah CA, Lowe KA, Paley P,et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125 [ J]. Cancer Epidemiol Biomarkers Prey, 2009,18 ( 5 ) : 1365-1372.

共引文献85

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部